RotaTeq

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

DiphtheriaPoliomyelitisIntussusception

70 competitors in Diphtheria

#DrugCompanyPhaseTrials

1

GSK 257049

GSK

Phase 3

22

Infanrix

GSK

Phase 3

13

Havrix

GSK

Phase 3

14

RotaTeq

Merck & Co.

Approved

15

Rsvpref3 Vaccine

GSK

Phase 2

16

Acthib

GSK

Phase 3

17

Vi-Polysaccharide Vaccine

Novartis

Phase 3

18

REVAXIS

Sanofi

Phase 3

19

Dtacp

CChangchun BCHT Biotechnology Co.

Phase 3

210

Vi-DT Vaccine

PPT Bio Farma

Phase 3

1Show 7 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Vaccine3 trials

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Recruiting·Sanofi·Phase 3·NCT06824194·2,320 enrolled

Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Active, not recruiting·Sanofi·Phase 3·NCT06736041·1,714 enrolled

RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)

Completed·Merck & Co.·Phase 3·NCT00443846·247 enrolled

Immunogenicity3 trials

Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)

Completed·Merck & Co.·Phase 3·NCT01337167·1,473 enrolled

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)

Completed·MMCM Vaccines B.V.·Phase 3·NCT01341639·1,250 enrolled

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

Completed·Merck & Co.·Phase 3·NCT03893448·1,720 enrolled

Rotavirus Vaccine3 trials

Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT01266850·1,384 enrolled

Safety, Reactogenicity and Immunogenicity of Heat-stable Rotavirus Vaccine (HSRV) in Adults and Infants

Completed·MMSD Wellcome Trust Hilleman Laboratories Pvt. Ltd.·Phase 1/2·NCT02728869·100 enrolled

Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected Mothers

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00880698·202 enrolled

Vaccination2 trials

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Active, not recruiting·Sanofi·Phase 3·NCT06824181·580 enrolled

Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination

Completed·Sanofi·Phase 3·NCT01839175·350 enrolled

Efficacy and Safety1 trial

Rotavirus Efficacy and Safety Trial (REST)(V260-006)

Completed·Merck & Co.·Phase 3·NCT00090233·69,274 enrolled

6 more indications

Randomized1 trial

Randomized, Controlled Single-blind Clinical Study to Assess Vaccine Interchangeability Between RV5 and RV1 Using Seven Combined Anti-rotavirus Prevention Programs

Completed·NNational Institute of Pediatrics, Mexico·Phase 3·NCT02193061·1,498 enrolled

Intussusception1 trial

Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study

Completed·—·Phase 4·NCT02542462·144 enrolled

Infants1 trial

A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)

Completed·Merck & Co.·Phase 3·NCT03620162·900 enrolled

Poliomyelitis1 trial

Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)

Completed·Merck & Co.·Phase 3·NCT04481191·400 enrolled

Diphtheria1 trial

Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060)

Completed·Merck & Co.·Phase 4·NCT01926015·192 enrolled

Unspecified2 trials

A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)

Completed·Merck & Co.·Phase 3·NCT01340937·2,808 enrolled

Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)

Completed·MMCM Vaccines B.V.·Phase 3·NCT01839188·385 enrolled

Details

Drug Info

Related News